Drug extends survival, reverses some neuromuscular damage in animals
About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than three years after diagnosis.
Now, new research led by Washington University School of Medicine in St. Louis indicates an investigational therapy for an inherited form of ALS extends survival and reverses signs of neuromuscular damage in mice and rats. The findings, published July 16 in The Journal of Clinical Investigation, have led to a phase one/two clinical trial to investigate whether the drug could benefit people with ALS whose disease is caused by mutations in a gene called SOD1.
“This drug had an impressive effect in mice and rats with just one or two doses,” said Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University. “We don’t know yet if this works in people, but we’re very hopeful. We’ve completed the first phase of safety testing, and now we’re working on finding the right dose.”
About 10 percent of ALS cases are inherited. Of those, about a fifth are caused by mutations in SOD1. Such mutations cause the SOD1 protein to be overly active, which suggests that reducing protein levels might help ALS patients with SOD1 mutations.
Patients with ALS have few options for treatment. Only two drugs have been approved by the Food and Drug Administration (FDA) for ALS, and both only modestly slow the course of the disease.
In collaboration with Ionis Pharmaceuticals, Miller and colleagues tested DNA-based compounds that block the body from making SOD1 protein.
Miller and colleagues at Ionis tested two such compounds – known as antisense oligonucleotides, or oligos for short – in mice and rats. The animals were genetically modified to carry a mutated form of the human SOD1 gene. By a few months old, such animals start having trouble walking and feeding themselves.
Mice were given an anti-SOD1 oligo or a placebo at day 50, and a second dose about six weeks later. The mice that received the active drug maintained their weight 26 days longer and lived 37 days longer than those given the placebo, an increase in life span of 22 percent.
As a comparison, the researchers also tested the treatment in rats. The rats that received an active oligo fared much better than the ones that received the placebo. They maintained their weight more than nine weeks longer and survived eight to nine weeks longer.
The oligos also reversed signs of neuromuscular damage in the animals. By nine weeks old, mice that carry the mutant SOD1 gene are already showing molecular signs of deteriorating neuromuscular function. To find out whether the drug could reverse this decline, researchers treated 9-week-old mice with an anti-SOD1 oligo or a placebo. Muscle function steadily improved over the next eight weeks in the mice that received the active drug, while it continued to decline in the placebo group. A sign of neurological damage rose in both groups, but it rose more than twice as quickly in the mice that received the placebo than the ones given the active oligo.
Miller’s colleague at the School of Medicine, Robert Bucelli, MD, PhD, an associate professor of neurology, leads a phase one/two clinical trial based on Miller’s research. The trial is designed to evaluate the safety of using the oligos in people. Initial safety testing did not identify any obvious hazards. Now, they are testing different doses and regimens to find the most effective way to reduce SOD1 levels without causing unacceptable side effects.
“The phase one/two trial is really still a safety trial,” Miller said. “There are not enough patients in it to really be able to accurately see an effect on disease. But we’re on the cusp of testing the hypothesis that people with ALS caused by mutations in SOD1 can benefit from this treatment. We predict the effect will be good, but we can’t know until we test it.”
Learn more: New ALS therapy in clinical trials
The Latest on: ALS therapy
via Google News
The Latest on: ALS therapy
- Custom Hops Blends Donated to Brewers for 8th Year of Ales for ALSon February 24, 2020 at 5:34 pm
Cambridge, MA and Yakima, WA — “Ales for ALSTM,” a philanthropic program benefitting the ALS Therapy Development Institute (ALS TDI), enters its 8th year of brewing, joining brewers from around the ...
- Boston researchers take innovative approach to finding ALS treatmentson February 24, 2020 at 2:58 pm
Boston researchers are taking a new approach to finding treatments for amyotrophic lateral sclerosis or ALS. They're testing three drugs in the same trial, the first time this approach has been tried ...
- New CRISPR base-editing technology slows ALS progression in miceon February 24, 2020 at 10:14 am
By combining the power of AAV gene delivery and split-base editors, Gaj and Perez-Pinera targeted and permanently disabled a mutant SOD1 gene, which is responsible for roughly 20% of inherited forms ...
- Angel Fund contributes $1 million for ALS research at UMass Medical Schoolon February 21, 2020 at 7:59 am
A study published last year by Brown showed that a single transplantation of a bone marrow-derived mesenchymal stem cell treatment for ALS called NurOwn was safe and well tolerated by patients. The ...
- New Google technology is helping people with ALS record their voiceson February 19, 2020 at 6:22 am
A groundbreaking new technology is offering freedom and hope to people with speech impairments, including those with ALS. Natalie Morales reports on the partnership between the ALS Therapy Development ...
- Gene therapy can protect against ALS and SMA-related cell deathon February 18, 2020 at 6:17 am
Researchers at Karolinska Institutet in Sweden and the University of Milan in Italy have identified a gene in human neurons that protects against the degeneration of motor neurons in the deadly ...
- Gene therapy can protect against ALS and SMA-related cell deathon February 16, 2020 at 4:00 pm
On conducting gene therapy experiments in animal models of ALS and SMA, the team was then able to show that the introduction of SYT13 saves sensitive motor neurons from degeneration in both diseases.
- Overcharged cell process clears dangerous ALS ‘junk’on February 13, 2020 at 7:18 am
The cool thing, as far as a therapy for ALS is concerned, is that we can also do the reverse,” Buchan says. “We can make the endocytosis pathway work better by over-expressing parts of it, like ...
- Amyotrophic Lateral Sclerosis Industry – Treatment, Outlook, Analysis, Research, Review To 2023on February 12, 2020 at 12:55 am
This report analyzes the amyotrophic lateral sclerosis market by type (familial ALS), by treatment (medication, physical therapy, speech therapy), by diagnosis (laboratory tests, imaging tests), ...
via Bing News